TNF and COVID-19: These findings are in line with other studies that did not reveal increased risk of severe COVID-19 in patients treated with biologics [11,13,14,20,21,22,23] and that specifically identified anti-TNF monotherapy as a rather protective drug against severe COVID-19 [11,24,25].